Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib + bevacizumab first-line real-world study in EGFR-mutant advanced NSCLC
ChiCTR2000029034Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of afatinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
afatinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000029034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029034.